Artikelen

This reading list we received from Drs entirely disinterested. E. Valstar, (Orthomolecular) doctor / biologist. We provide this list are unchanged for publication. .

Scroll down for list.

Valstar wrote the book Nutritional intervention in cancer, a signal to the conventional oncology. See description on page, etc. ISBN cancer rates. We want to mention that we have no business or substantive ties with Engelbert Valstar, but this book and lists seem to us so interesting that we want to change places. Questions / comments can be sent to the editor: redactie@kanker-actueel.nl We will keep your questions / comments to be forwarded Valstar. Also on this list and further information on this page is of course our disclaimer applies.

More detailed descriptions and other studies see and nutrition research. And we try to at least the abstract and the results of the Phase III trials and pivotal Phase II studies in the literature list and nutrition research. or current mainstream research to publish or not fitted comments.

For regular treatments in general because the only randomized study possible side effects. Moreover, a randomized study of conventional treatments often never implemented. This assertion of Valstar based on relevant literature is in NTvG (see NTvG 136: 709-710, 1992) by the respective oncologists not contradicted.
See also Nutritional Oncology, Heber D. et al ISBN 0-12-335960-0, the book was edited by Harvard and by the Memorial Sloan Kettering Institute! ).
(Editors note: See extensive bibliography in the book of Valstar Nutritional intervention in cancer, a signal to the conventional oncology and now as published on this site)..

To this list are Hans Houtsmuller, Ed Woerlee Johan Bolhuis and important contributions.

Bibliography of studies cancer and nutrition / supplementation. Studies: 501 t / m 600

501) T Grau et al, Nutr Hosp 18: 159-66, 2003: Medium-chain triglycerides (MCT) instead of LCT appears partly given parenterally to patients with severe malnutrition the number of infections to reduce and improve survival.

502) Macia E, et al, Nutrition 7:205-9, 1991; Patients as nutritionally precisely guided and radiation therapy do better than patients on clinical grounds, while those irradiated food ad libitum.

503) Ikeda S et al; Gan No Rinsho 31: 1079-1087, 1985, from Streptomyces olivoreticuli Bestatin, randomized study as an adjunct to improve the 5-year survival of melanoma patients.

504) Ikeda S et al; Gan To Kagaku Ryoho 12: 77-85, 1985; Same result as in reference 503.

505) R LaBianca et al, Ann Oncol 8: 169-74, 1997; In metastatic colorectal cancer appear normal and extra high-dose leucovorin as effective for potentiation of 5-FU.

506) Delanian S et al, J Clin Oncol 21:2545-50, 2003, Vitamin E has a preventive effect with pentoxifylline Attn fibrositis as side effects of radiation, individually, these agents lack the ability to side effect.

507) Muss HB et al, Cancer 47:2295-2301, 1981; A methanol extract of BCG (not a live vaccine) had no effect on probability regression, degree of complications and survival in breast cancer patients receiving chemotherapy. See also reference 451.

508) Li LN et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 575-9, 2003; Xiaoji improves long-term survival of patients with inoperable NSCLC in randomized studies significantly.

509) Yonemura Y et al, Hepatogastroenterology 48: 1776-1782, 2001, Hyperthermia as an adjuvant to gastric cancer chemo next five years operation improves survival from 43 to 61% if only operate in addition to chemotherapy as additional treatment is applied.

510) JY Kim and Bae HS, Gastric Cancer 4: 27-33, 2001; In this study in cancer patients with a lower forecast showed hyperthermia chemotherapy after curative surgery, in principle, improve survival compared to such an operation and chemo alone.

511) Popiela T et al, BCG appears to chemo surgery for gastric cancer to improve survival more than surgery and chemotherapy alone.

512) Han JQ et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 17: 465-6, 1997; Herbal Extract Xuefu Zhuyu improves in patients with primary liver cancer is the result of radiation that is disease-free survival is not only the survival sec is significantly better randomized study.

513) P Duan and HM Wang, Xi Yi Jie He Zh Zh Za Zhi 22: 515-7, 2002; Astragalus reduces randomized study in patients with cancer who receive chemotherapy side effects and reduces disease progression.

514) Would YH and Liu XM, Zhongguo Zhong Xi Yi Jie He Za Zhi 23:733-5, 2003; Astragalus improves survival of patients with non-small cell lung cancer who receive chemotherapy and improves their quality of life.

515) Wei YF et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 258-60, 2003, in a pilot study in leukemia patients had many immune parameters are significantly better in the group receiving chemo shengfu received, the regression probability was in the shengfu group though this difference was even greater as not significant.

516) Cai HB et al; Di Yi Da Xue Bao Yi June 22: 1112-3, 2002, TCM (traditional Chinese Medicine) reduces randomized study side effects of radiotherapy and thus improves the quality of life.

517) Neifeld JP et al, J Surg Oncol 28: 137-45, 1985; adjuvant setting of surgically treated squamous cell carcinomas of the throat with Corynebacterium parvum throat cancer improves survival in randomized trials.

518) Liu F et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 265-7, 2003; Guliu, a Chinese herbal mixture improves the results of randomized study regular treatment for bone metastases due to breast cancer is not significant, but the quality of life is significantly.

519) Lan Jiang X and Y, Y Chi Tradition Med 23: 32-4, 2003, Chinese herbs to improve the long-term survival of patients with advanced lung cancer radiotherapy treatment.

520) Ichinose Y et al, JNCI 95: 605-10, 2003; Bestatin adjuvant improves the survival of patients operated due to a squamous cell carcinoma of the lung stage 1.

521) Wang Y et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 18: 273-5, 1998;-Ochrea Inula extract appears just as effective for vomiting associated with cisplatin therapy to combat as regular medication, of course, to check the weather randomized research.

522) CQ Bai et al, Zhonghua Liu Xing Bing Xue Za Zhi 24: 130-4, 2003; Injection Shenqi Fuzheng randomized study significantly reduces the side effects of chemo.

523) Liu J et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 21: 262-4, 2001; Guben Yiliu 3 with "moxibustion" will reduce quality of life through chemo 4 ways to measure in randomized studies.

524) Han JQ et al, Zhongguo Zhong Xi Yi Jie He Za Zhi 15:710-2, 1995; Fuchunpian given alongside radiotherapy for patients with a demonstrable negative nasopharynxcarcinoom affects the course; fuchunpian should therefore certainly in this type of cancer are discouraged.

525) T Yasumitsu et al, Acta Oncol 29: 827-31, 1990; Bestatin appears as an adjuvant to the survival of Patie: Restaurants surgery for a squamous cell carcinoma to improve, which was not detectable with respect to other types of lung cancer. See also reference 520.

526) Takada M et al, Acta Oncol 29: 821-5, 1990; Bestatin in addition to conventional treatment for inoperable lung cancer only in squamous cell carcinomas more regressions, the median survival was significantly better but only almost got plaveiselcelcarcinoompatiënten that bestatin, p = 0.051.

527) Niimoto M and Hattori T et al, Biomed Pharmacother 45: 121-4, 1991; Bestatin as an additional adjuvant treatment of patients operated on for gastric cancer patients improves survival.

528) Niimoto M et al, Jpn J Surg 20: 186-91, 1990; Bestatin as an additional adjuvant for treatment of gastric cancer patients operated on in this small study to improve survival significantly in patients treated according to standard criteria, an inferior prognosis.

529) Tanaka T et al; Gan To Kagaku Ryoho 12: 125-33, 1985; Bestatin improves as additional adjuvant randomized trial in the treatment of gastric cancer disease-free survival.

530) K Yoshinaka et al; Gan To Ryoho 15: 493-8, 1988; Bestatin showed the recurrence of stomach cancer can reduce, but in the five years survival was no effect.

531) Bedikian AY et al, Am J Clin Oncol 7: 399-404, 1984; Thymostimuline chemo for patients with advanced large cell lung cancer improves survival of these patients, certainly not, although there were significantly fewer serious side effects.

532) Yang JK et al, Zhongguo Zhong Xi Jie He Za Zhi 23:580-2, 2003; Weichangán (WCA) improves survival in operated gastric cancer patients who receive additional chemotherapy.

533) Blomgren H et al, Cancer Immunol Immunother 25: 41-6, 1987; Bestatin alongside radiotherapy for bladder cancer improves disease-free survival in randomized studies.

534) Kumamoto Y et al, Hinyokika Kiyo 31: 1861-1883, 1985; Bestatin significantly slows unilateral recurrences of bladder cancer after adjuvant treatment with bleomycin.

535) Blomgren H et al, Biomed Pharmacother 38: 143-9, 1984; Bestatin as an additional adjuvant for patients with bladder cancer due to radiation therapy improves disease-free survival.

536) Uchibayashi T et al, Int J Clin Pharmacol Ther 33: 465-8, 1995; Bestatin chemo in this study reduced the risk of recurrence of bladder cancer significantly compared with chemo alone.

537) Blomgren H et al, Acta Oncol 29: 809-12, 1990; Bestatin showed in this study the survival of bladder cancer patients who received radiotherapy did not improve, with the numbers 533534 en535's certain that bestatin case of irradiation for bladder cancer disease-free survival improves.

538) Papas AS et al, Bone Marrow Transplant 31: 705-12, 2003, A calcium phosphate solution is mucositis as a side effect of bone marrow transplantation, according to randomized, double-blind study.

539) DiSaia PJ et al, Gynecol Oncol 26: 386-97, 1987; Corynebacterium parvum enhances the survival of cervical cancer patients receiving radiation therapy are not treated.

540) MH Mignot et al, Br J Cancer 44: 856-62, 1981; Corynebacterium parvum as an adjuvant reduces the risk of recurrence after surgery for cervical cancer randomized study significantly.

541) Kurita S et al; Gan To Kagaku Ryoho 11: 2742-50; Bestatin prolongs the remission duration of patient after chemotherapy: seeding with ANLL and prolongs their survival.

542) and Ota K Ogawa N, Biomed Pharmacother 44: 93-101, 1990; In this study, bestatin was found in ANLL remission duration after chemotherapy and prolong life.

543) Urabe A et al, Ann Hematol 67: 63-6, 1993; In this randomized study again bestatin significantly prolonged the remission duration in patients with ANLL, the longer survival of bestatinpati: Grafting, however, was not yet significantly longer.

544) K. Ota et al, Cancer Immunol Immunother 23: 5-10, 1986; with bestatin revealed in this study to patient: Grafting with ANLL again a longer survival reached.

545) Kobayashi T et al, J Clin Oncol 14: 204-13, 1996, Bestatin improves disease-free patient survival: grafts with acute myeloid leukemia who have had no chemotherapy, AML and ANLL are not congruent, so this result on its own .

546) Hernandez Munoz G, Pluchino S, Maturitas 44: S59-65, 2003, Cimicifuga racemosa reduces number and severity of hot flushes that patient: Entes receive tamoxifen for breast cancer include the use.

547) JS Jacobson et al, J Clin Oncol 19: 2739-45, 2001, Cimicifuga racemosa decreased in this randomized study the number and intensity of hot flushes is not, perhaps it is because the hot flushes are fewer in number / severity were (as used 1 in 3 women are not even Nolvadex).

548) Newlands ES et al, Br J Cancer 34: 174-9, 1976; BCG enhances the effect of chemotherapy in patient: Grafting with metastatic melanoma, the survival does not get any better.

549) Paterson AH et al, Rec Results Cancer Res 68: 387-92, 1978; adjuvant BCG decreases in relation to staging the risk of recurrence in patients treated for malignant melanoma.

550) ariyan S et al, Surgery 92: 459-63, 1982, Intra-lymphatic administration of a methanol extract of BCG reduces the risk of recurrence and mortality from malignant melanoma.

551) Wood WC et al, Surgery 83: 677-81; DTIC plus BCG as an adjuvant appears to be the disease-free survival of patients operated due to malignant melanoma more than just improving DTIC.

552) Ohwada S et al, Br J Cancer 90: 1003-1010, 2004, in addition to adjuvant chemotherapy PSK reduces the mortality of patients operated on for colon cancer Dukes B or C in this study significantly, this is yet another investigation, which remains the standard oncology?

553) Morton DL et al, Aust NZJ Surg 48: 49-52, 1978, BCG only prolongs the lives of patients with lymph node metastases of malignant melanoma.

554) Veronesi U et al, N Engl J Med 307:913-6, 1982; BCG in stage 1 / 2 malignant melanoma, sometimes in combination with chemotherapy as an additional adjuvant after surgery improves survival only not significant.

555) W Olszewski, Angiology 51: 25-9, 2000, A flavonoidenextract reduces congestion by edema in breast cancer in randomized double-blind study.

556) Quirt IC et al, J Clin Oncol 9: 729-35, BCG reduces the risk of recurrence and mortality in patients at high risk of recurrence of a malignant melanoma is only just not significant.

557) JW Reid et al, Rec Results Cancer Res 80:219-26, patients with large cell lung cancer improves BCG in case of an impaired immune disease-free survival.

558) Serrou B et al, Rec Results Cancer Res 80: 157-61, 1982; BCG in this study significantly reduced the relapse rate after successful chemotherapy due to breast cancer stage 3 or 4.

559) SA Brosman, J Urol 128: 27-30, 1982, BCG reduces the risk of recurrence after surgery because of bladder cancer in this randomized study significantly.

560) Lamm DL et al, J Urol 128:931-5, 1982; In this randomized study shows BCG, the recurrence of bladder cancer costs.

561) Senn HJ et al, Recent Results Cancer Res 80: 177-84, 1982; BCG as an additional adjuvant chemo for breast cancer patients improves disease-free survival and survival sec.

562) Vu Van H et al: Presse Med 11:3637-9 nouV, 1982, in patients in complete remission after chemotherapy for AML improves BCG remission duration and survival significantly.

563) Robinson E et al, Cancer Chemother Pharmacol 8: 35-40, 1982, A BCG extract improves disease-free survival of colorectal cancer patient: ë: Restaurants Dukes C, but by patient: ë: Restaurants Dukes' stage B is not.

564) Herr HW et al, Urology 25: 119-23, 1985; In this randomized study showed the risk of recurrence BCG for bladder cancer patients to decrease.

565) DL Lamm, J Urol 134:40-7, 1985, and in this randomized study shows BCG, the risk of recurrence in bladder cancer patients operated on costs.

566) Hudson, MA et al, J Urol 138:295-8, 1987; Repeat BCG therapy improves favorable outcome of the first BCG treatment for bladder cancer patients do not.

567) Shank B et al, Cancer 56: 2771-8, 1985, thymosin fraction 5 of chemo plus radiation therapy improves outcome in patients with locally small cell lung cancer in this small randomized trials. See also numbers 33, 36 and 198. The overall conclusion is that, thymostimuline in treating this type of cancer is important especially in case of a less well functioning immune system (which is more likely than extensification local disease).

568) Pinsky CM et al, Cancer Treatm Rep 69:47-53, 1985; In this randomized study shows BCG, the risk of recurrence in patients with bladder cancer reduction.

569) K. Mori et al, Urol Int 41: 254-9, 1986; In this randomized study showed a relapse of BCG-treated bladder cancer far more combat than adriamycin.

570) Gil MJ et al; Nutritition 13:26-31, 1997; In malnourished patients who undergo surgery because of colon cancer and given parenteral nutrition, additional water and salt appears useless, the risk of pulmonary complications, this appears to be increasing.

571) Badal Ament RA et al, J Clin Oncol 5: 441-9, 1987; In this randomized study in patients operated for bladder cancer a local disease-free survival with BCG significantly better.

572) Net NO Junior et al, Arch Esp Urol 44: 1025-8, 1991, as an adjunct for the prevention of recurrence in bladder cancer patients locally flush with BCG better than oral BCG.

573) Rintala E et al, Eur Urol 20: 19-25, 1991; BCG as adjuvant treatment for superficial bladder cancer in all respects superior to mitomycin-C.

574) Francesco Bassi P et al, Arch Esp Urol 43: 503-7, 1990, BCG Pasteur show about as well as an adjunct in the treatment of bladder cancer as conventional BCG.

575) Yamamoto T et al, Nippon Hinyokika Gakkai Zasschi 81: 997-1001, 1990, BCG is also evident in this randomized study the risk of recurrence in patients treated for superficial bladder cancer can be reduced.

576) Witjes JA et al, Eur J Cancer 29: 1672-6, 1993, two different types of BCG in this study appear as effective as an adjunct to treatment for superficial bladder cancer and mitomycin-C.

577) T Ao et al, Hinyokika Kiyo 39: 987-91, 1993; BCG as an additional adjuvant for the treatment of bladder cancer after local two different chemotherapy shows no significant further improvement in disease-free survival, a meta-analysis of the aforementioned and still be called studies of BCG and bladder cancer is obviously unequivocally positive.

578) F. Pagano et al, J Urol 146:32-5, 1991; In this study, a relatively low dose of the BCG Pasteur strain by flushing as effective as an adjunct to bladder cancer patients and higher.

579) Yabusaki N et al, Nippon Hinyokika Gakkai Zasschi 82: 290-6, 1991; BCG after mitomycin C as an additional adjuvant reduces the additional risk of recurrence in patients treated for superficial bladder cancer.

580) Lamm DL et al, J Urol 145: 738-40, 1991; Adjuvant therapy with BCG for bladder cancer patients by flushing alone is as effective as using washes and intradermal injection.

581) Ludwig Lung Cancer Study Group, Cardiovasc Surg 89:842-7, 1985; Corynebacterium parvum as adjuvant treatment after surgery for lung cancer stage 1 or 2 intrapleural administration appears unfavorable compared to placebo: This bacterium showed worse survival in this study . See also 351 354 355 and 356, the total result of C. parvum in lung cancer is now nil, C. intrapleural parvum should certainly not be alone and possibly in patients with squamous cell carcinoma of the lung, especially when the stage 3 covers.

582) Lamm DL et al, N Engl J Med 325: 1205-9, 1991; Intravesical BCG as adjuvant treatment for superficial bladder cancer superior to rinsing with adriamycin.

583) Martinez-Pineiro JA et al, J Urol 143: 502-6, 1990; BCG wins in this study as an adjunct to bladder cancer in both adriamycin and thiotepa.

584) DeBruyne FM et al, Urology 31:20-5 (suppl) 1988; In this study, flushing of the bladder after adjuvant treatment of superficial bladder cancer is as effective as rinsing with mitomycin C.

585) Lobo DN et al, Lancet 359: 1812-8, 2002, Additional salt and water after bowel resection part slows it starting up again on the stool and prolongs hospital stay, this result is in line with Moerman / Houtsmuller.

586) Ravasco P et al; IJ Radiate. Oncol Biology Physics, 57: S220-1, 2003, providing individual nutritional advice during irradiation show based on randomized quality of life during radiation therapy to improve next focused mainly additional protein supplementation was given. See also reference 187.

587) Ravasco P et al; IJ Radiation Oncology Biology Physics 57: S440, 2003, Individual and dietary protein to a lesser extent, additional randomized study deterioration of the quality of life during radiotherapy due to throat cancer. See also 586 and 187.

588) Dencausse Y et al, Onkologie 25: 402-3, 2002, 5-FU as adjuvant treatment for over half of cancer patients operated on for colon cancer stage 3 is as effective as adjunctive therapy when given for 1 year.

589) WA Bleeker et al, Ann Oncol 11: 547-52, 2000, Low dose leucovorin to improve the outcome of 5-FU plus metronidazole undetectable adjuvantsituatie further into the stage 3 of colon cancer. We knew already that 5-FU with a normal dose leucovorin preferable to 5-FU and metronidazole, see no 321. The result of No 589 is therefore inappropriate.

590) Poon MA et al, J Clin Oncol 9: 1967-1972, 1991; leucovorin with 5-FU shows randomized study in patients with advanced colorectal cancer a better survival than 5-FU alone.

591) A. Abad et al, Cancer 75: 1238-1244, 1995; leucovorin with 5-FU prolongs patients with advanced colon cancer life compared 5-FU alone.

592) Borner MM et al, Ann Oncol 9: 535-41, 1998; leucovorin plus 5-FU also in this study in patients with an advanced form of cancer last longer than with 5-FU alone the case.

593) Colombo N et al, Int J Gynecol Cancer 5:81-86, 1995, Glutathione reduces cisplatin neurotoxicity and optimize their application in randomized studies in patients with relapsed ovarian cancer.

594) E Fonseca et al, J Infusion Chemother 6: 217-20, 1996, leucovorin improves the result of 5-FU in advanced nasopharynxcarcinomen not, according to randomized study.

595) Akaza H et al, Cancer 75:552-9, 1995; BCG shows two of the three superficial bladder tumors to regress to bring, maintenance BCG shows the result does not improve.

596) Martinez-Pineiro JA et al, Eur Urol 27 Suppl 1: 13-8, 1995, a third of this group previously given dose BCG appears as effective as the original in the treatment of bladder cancer, the lower dose, with demonstrable fewer adverse reactions.

597) received S et al, J Urol 156: 962-6, 1996, BCG and mitomycin-C in this randomized study as an adjunct in the treatment of superficial bladder cancer equally effective.

598) Lüftenegger W et al, J Urol 155: 483-7, 1996, BCG reduces the risk of local recurrence significantly bladder cancer, BCG intradermally further improves the result does not.

599) Lund C Holm et al, J Urol 156:372-6, 1996, BCG as adjuvant treatment for locally treated bladder cancer appears superior to mitomycin C-ie, fewer relapses and longer disease-free survival with BCG than with mitomycin-C.

600) Melekos MD et al, Oncology 53: 281-8, 1996, BCG appears in a similar survey as number 599 among superior to epirubicin.